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Purpose: The current studies were conducted to determine whether the cyclin-dependent kinase inhibitors, p21Cip1 (p21
cyclin-dependent kinase-interacting protein 1) and p16INK4a (p16 cyclin-dependent kinase inhibitor 1A), help mediate
G1-phase inhibition in human corneal endothelial cells (HCEC) by testing the effect of siRNA (small interfering RNA)-
mediated down-regulation of the expression of these inhibitors on cell cycle entry and proliferation in HCEC cultured
from older donors.
Methods: HCEC were obtained from National Disease Research Interchange, Philadelphia, PA, and cultured according
to published methods. Cells were electroporated in the presence of either a non-silencing siRNA control or p21+p16
siRNA. The efficiency of siRNA transfer was observed by fluorescence microscopy of Cy3-labeled control siRNA.
Viability was determined by direct counting of cells before and after electroporation. The ability of p21+p16 siRNA to
decrease the protein expression of p21Cip1 and p16INK4a was determined by semi-quantitative analysis of western blots.
The effect of siRNA treatment on cell cycle progression and proliferation was determined 1, 5, and 11 days after
electroporation by counting Ki67-positive cells and total DAPI-stained nuclei.
Results: siRNA was efficiently transferred to HCEC by the electroporation method. The average cell loss was 41.25% at
24 h following electroporation. Protein levels of both p21Cip1 and p16INK4a were significantly decreased as the result
of p21+p16 siRNA treatment. This treatment significantly increased the average number of Ki67-positive cells over
controls and increased the total number of cells in a time-dependent manner.
Conclusions: Both p21Cip1 and p16INK4a are involved in negative regulation of the cell cycle in HCEC and, thereby,
provide an effective barrier to cell division. The siRNA-induced reduction in expression of these proteins increased the
number of cells entering the cell cycle, as well as total cell numbers. Thus, reduction of the levels of p21Cip1 and p16INK4a
could be useful in the development of treatments to induce transient cell division to increase corneal endothelial cell
density.
Human corneal endothelial cells (HCEC) in vivo retain
proliferative potential, although they do not normally divide
as a means of tissue repair [1]. The ability of HCEC to divide
has been demonstrated using ex vivo cornea model systems
in which cell-cell contacts were released either by mechanical
wounding  of  the  endothelium  [2]  or  by  treatment  of  the
endothelium with EDTA to release cell-cell junctions [3,4].
In both ex vivo model systems, HCEC entered the cell cycle
and  underwent  cell  division  after  mitogenic  stimulation.
HCEC are also able to divide in culture in the presence of
appropriate mitogens [5,6]. Studies using both the ex vivo
cornea wound models and cultured cells clearly indicate that
the  proliferative  capacity  of  HCEC  decreases  in  an  age-
dependent manner [2,6].
The endothelium plays a key role in maintaining corneal
transparency.  As  such,  it  is  important  to  find  methods  to
increase the density of HCEC in patients at risk for vision loss
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due to low endothelial cell density. One important way to
increase the density of HCEC is to take advantage of their
capacity  to  divide.  Current  research  goals  related  to  the
proliferative capacity of HCEC include: 1) Inducing in vivo
cell division to repair corneal endothelium following trauma;
2) Increasing the density of HCEC in ex vivo corneas to be
used for keratoplasty; and 3) Promoting division of HCEC in
culture  to  provide  a  sufficient  population  of  healthy,
functional HCEC for tissue bioengineering. To achieve these
goals, this laboratory has conducted studies to explore the
molecular mechanisms that regulate proliferation of HCEC.
The cell cycle is divided into four distinct phases, leading
to the formation of daughter cells. Studies have demonstrated
that HCEC in vivo are inhibited in G1-phase of the cell cycle
[7,8]. G1-phase is the initial portion of the cell cycle that occurs
upon exposure to mitogens. During this phase, cells prepare
for the process of DNA duplication, which occurs in S-phase.
Cells will remain in G1-phase until all conditions required for
normal DNA duplication have been met. Movement of cells
into S-phase requires activation of the transcription factor,
E2F,  which  regulates  the  expression  of  several  proteins
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897required for DNA duplication [9]. In the G0- (resting phase of
the cell cycle) and early G1-phase, the retinoblastoma protein,
Rb, tightly binds E2F, maintaining it in an inactivated state.
Following  mitogenic  stimulation,  the  Rb  protein  becomes
hyperphosphorylated  by  specific  cyclin-dependent  kinase
complexes, resulting in the subsequent activation of E2F.
Negative regulation of G1-phase is mediated, in part, by the
activity of cyclin-dependent kinase inhibitors (CKIs). These
inhibitors help prevent the hyperphosphorylation of Rb and
subsequent activation of E2F [10-12]. The p27Kip1 (kinase
inhibitor protein-1) inhibitor is expressed at relatively high
levels in mitogen-starved cells [13] and helps mediate both
contact-dependent and transforming growth factor-β-induced
inhibition  of  proliferation  [14].  The  CKI,  p21Cip1  (p21
cyclin-dependent  kinase-interacting  protein  1),  is  an
important transcriptional target of the tumor suppressor, p53,
and  mediates  both  G1-  and  G2-phase  checkpoint  arrest  in
response to stresses, such as oxidative DNA damage [15,16].
Molecular studies have demonstrated an important role for
p16INK4a (p16 cyclin-dependent kinase inhibitor 1A) in the
development  of  cellular  senescence  [17].  Induction  of
p16INK4a  expression,  via  various  molecular  biologic
approaches, results in G1-phase arrest and development of a
senescent phenotype [18,19]. Decreasing the expression of
p21Cip1 or p16INK4a in knockout mice or in cells in which
p21Cip1 or p16INK4a has been down-regulated by treatment
with  inhibitory  peptides  [18],  antisense  oligonucleotides
[20], or small interfering RNA (siRNA) [21], can overcome
negative G1-checkpoint regulation [22], promote a temporary
escape from senescence [23], and induce cell proliferation
[20].
Corneal  endothelial  cells  in  vivo  express  p27Kip1,
p21Cip1,  and  p16INK4a  [8,24].  Western  blot  analysis  of
HCEC isolated from young (≤30 years old) and older donors
(≥50 years old) [25] indicates that there is no significant age-
related  difference  in  the  relative  expression  of  p27Kip1.
Interestingly, treatment of confluent cultures of HCEC with
p27Kip1 siRNA promoted proliferation of cells cultured from
young, but not older donors [26]. This suggests that G1-phase
in  HCEC  from  older  donors  is  negatively  regulated  by
additional mechanisms. Western blot analysis of HCEC also
revealed that the expression of both p21Cip1 and p16INK4a
increases significantly with donor age, implicating these CKIs
as  mediators  of  the  age-related  decrease  in  proliferative
capacity observed in these cells.
To develop methods to induce transient proliferation of
HCEC, it is important to explore the molecular mechanisms
involved in regulation of the cell cycle in HCEC from older
donors. This is especially important because it is this segment
of the population that normally has vision loss due to low
endothelial cell density and it is also this segment of the
population that provides the majority of donor corneas to be
used  for  transplantation  or  for  use  in  corneal  tissue
bioengineering.  The  current  studies  were  conducted  to
determine whether p21Cip1 and p16INK4a help mediate G1-
phase inhibition in HCEC by testing the effect of siRNA-
mediated  down-regulation  of  the  expression  of  these
inhibitors  on  cell  cycle  entry  and  proliferation  in  HCEC
cultured from older donors.
METHODS
Human donor corneas and culture of HCEC: Donor human
corneas  were  obtained  from  National  Disease  Research
Interchange (NDRI), Philadelphia, PA. Donor confidentiality
was maintained by the eye bank, NDRI, and this laboratory
according to the tenets of the Declaration of Helsinki. Table
1  presents  relevant  donor  information  and  indicates  the
specific experiments the corneas were used for. Corneas were
accepted for study based on published exclusion criteria [6].
Corneas were accepted only if the donor history and condition
of  the  corneas  indicated  no  damage  to  the  health  of  the
endothelium. Endothelial cell counts for all accepted corneas
were  at  least  2,000  cells/mm2.  HCECs  were  cultured
following  previously  described  protocols  [5,6].  Briefly,
Descemet’s membrane with the attached endothelium was
carefully dissected from corneas in small strips and incubated
overnight  in  OptiMEM-I  (Invitrogen-Life  Technologies,
Carlsbad,  CA)  supplemented  with  8%  fetal  bovine  serum
(FBS: Hyclone, Logan, UT) to stabilize the cells. After gentle
centrifugation, strips were incubated in 0.02% EDTA at 37 °C
for  1  h  to  loosen  cell-cell  junctions.  Cell  junctions  were
mechanically  disrupted  by  forcing  the  tissue  and  culture
medium through the narrow opening of a flame-polished glass
pipette. Cells were pelleted and then resuspended in culture
medium.  Culture  medium  consisted  of  OptiMEM  I
supplemented with 8% FBS, 5 ng/ml epidermal growth factor
(EGF  from  mouse  submaxillary  gland;  Upstate
Biotechnologies,  Lake  Placid,  NY),  100  μg/ml  pituitary
extract (Biomedical Technologies), 20 μg/ml ascorbic acid,
200  μg/ml  calcium  chloride,  0.08%  chondroitin  sulfate,
antibiotic/antimycotic solution diluted 1/100 (all from Sigma-
Aldrich, St. Louis, MO) and 50 μg/ml gentamicin (Invitrogen-
Life Technologies). After passage 2, EGF and pituitary extract
were removed from the medium. The majority of HCEC were
passaged 2–4 times before use in these experiments.
Electroporation of siRNA: Confluent HCEC were removed
from the culture dish by treatment for 6–8 min with 0.05%
trypsin-EDTA  (Invitrogen-Life  Technologies)  at  37  °C.
Trypsin activity was inhibited by addition of culture medium
containing 8% FBS. The trypsinized cells were incubated for
3 min in the presence of trypan blue and counted using a
Cellometer Auto T4 instrument (Nexcelom Bioscience LLC,
Lawrence,  MA).  Analysis  of  the  cell  counts  indicated  an
average viability of 87.4% following trypsinization of the
cultured cells (data not shown). The number of viable cells
obtained  following  trypsinization  acted  as  a  basis  for
calculation  of  the  number  of  cells  to  be  used  for
electroporation. An Amaxa Nucleofector II device (Lonza,
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Mammalian Endothelial Cells using the T-23 program were
used for electroporation. Methods and reagents were based on
Amaxa-recommended  protocols.  Three  different  p21Cip1
siRNAs  and  three  p16INK4a  siRNAs  (all  siRNAs  from
Applied Biosystems/Ambion, Austin, TX) were tested for
their  ability  to  effectively  reduce  protein  expression  as
indicated by semi-quantitative analysis of western blots (see
below). A non-silencing siRNA control (Silencer negative
control  #1  siRNA;  Ambion  4611;  Applied  Biosystems/
Ambion)  was  used  for  most  experiments.  Following
preliminary studies, 1 μg siRNA per 5×105 cells in 100 μl
Basic Nucleofector Solution was found to be most efficient
for  electroporation  of  HCEC.  Immediately  following
electroporation, culture medium (without EGF or pituitary
extract), which was pre-warmed to 37 °C, was added to the
cells.  Cells  were  then  plated  as  required  for  the  specific
experiment.
Detection of siRNA transfer: HCEC were electroporated as
above with 1 μg Silencer Cy3-labeled Negative Control #1
siRNA (Ambion AM4621; Applied Biosystems/Ambion) and
plated  in  normal  culture  medium.  At  24  h  following
electroporation, Cy3-labeled siRNA transfer was visualized
using a Nikon Eclipse TS100 inverted microscope with an epi-
fluorescence  attachment  and  a  Nikon  Coolpix995  digital
camera (Nikon Instruments, Melville, NY).
Test of viability following electroporation: HCEC were grown
to confluence and then removed from the culture dish by
trypsin-EDTA treatment. Trypsinized cells were treated with
trypan  blue  and  counted  using  a  Cellometer  Auto  T4
instrument, as described above. Equal numbers of viable cells
were  either  not  electroporated  or  electroporated  in  the
presence of Silencer negative control #1 siRNA (Ambion
4611; Applied Biosystems/Ambion) as above. Cells were then
plated in culture medium without EGF or pituitary extract and
viability was determined 24 h later. To test for viability, cells
were gently washed, then trypsinized, treated with trypan
blue,  and  counted  using  the  Cellometer.  The  percent
difference  in  cell  counts  between  the  non-electroporated
control and the electroporated sample was calculated in five
separate experiments and the results averaged.
Western blot detection of p21Cip1 and p16INK4a: HCEC
were  either  not  electroporated  or  electroporated  in  the
presence of siRNA. Cells were then cultured for 72 h (in
medium  without  EGF  or  pituitary  extract)  before  protein
extraction. Protein was extracted by incubating HCEC for 30
min  at  4  °C  in  lysis  buffer  containing  1%  Triton  X-100,
250 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl (pH 7.4),
10  µg/ml  aprotinin,  10  µg/ml  leupeptin,  1  mM
phenylmethylsulfonyl fluoride, 50 mM sodium fluoride, and
0.1 mM sodium orthovanadate (all from Sigma), followed by
homogenization and centrifugation. Equal concentrations of
soluble protein were loaded on 10% Bis-Tris gels (Invitrogen-
Life Technologies) for SDS–PAGE and then transferred to a
polyvinylidene  difluoride  (PVDF)  membrane  (Millipore,
Bedford, MA). The membrane was incubated overnight at
4 °C in p21Cip1 mouse monoclonal antibody diluted 1:2,000
(Cell Signaling, Danvers, MA), p16INK4a rabbit polyclonal
antibody  diluted  1:400  (Santa  Cruz  Biotechnology,  Santa
Cruz, CA) or beta-actin mouse monoclonal antibody diluted
1:3,000 (Sigma). All antibodies were diluted in 5% non-fat
dry  milk,  plus  0.1%  Triton  X-100  in  phosphate-buffered
saline (PBS; Invitrogen-Life Technologies). Membranes were
then rinsed 2 times for 10 min each with PBS containing 0.1%
TABLE 1. DONOR INFORMATION.
Donor age Hours Days Cause of death Experiment
27 06:00 2 Pulmonary Edema Western blot
28 14:00 3 Internal Bleeding/MVA siRNA transfer/western
52 07:30 3 Ischemic Cardiomyopathy Viability test
53 10:30 3 Myocardial Infarction Viability test/Ki67 ICC
54 18:00 3 Myocardial Infarction Ki67 ICC
57 07:00 3 Cardiac Arrest Ki67 ICC
61 06:00 3 Breast Cancer Viability test/Ki67 ICC
68 09:30 3 Cardiogenic Shock Western blot
69 06:50 3 Myocardial Infarction Western blot
71 07:00 3 Hypokalemia Western blot
73 14:00 3 Heart Disease Western blot
73 12:00 2 Electrocution Viability test/Ki67 ICC
74 05:30 3 Myocardial Infarction Viability test
77 11:00 3 Myocardial Infarction Western blot
The “Hours” column indicates the number of hours between death and corneal preservation and the “Days” column indicates
the number of days of corneal preservation in Optisol-GS at 4 °C.
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HRP-conjugated  donkey  anti-mouse  or  anti-rabbit  IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA)
diluted at 1:5,000 in 5% non-fat dry milk in 0.1% Triton
X-100/PBS. After washing the membranes 2 times for 10 min
with PBS containing 0.1% Triton X-100, antibody binding
was  detected  using  a  chemiluminescent  substrate
(SuperSignal West Pico or West Femto; Pierce, Rockford, IL).
Membranes were then exposed to film to permit visualization
of specific protein expression. Semi-quantitative analysis of
protein expression was performed by densitometry using NIH
Image  software  (NIH  Image  1.34;  National  Institutes  of
Health,  Bethesda,  MD).  Expression  of  p21Cip1  and
p16INK4a was normalized relative to that of beta-actin.
Assessment of the effect of p21+p16 siRNA treatment on cell
cycle activity: HCEC cultured from the corneas of five older
donors (>50 years old) were grown to confluence as above,
removed  from  the  tissue  culture  plate  by  treatment  with
trypsin/EDTA, then transferred to culture medium containing
8% FBS to inhibit the trypsin activity. Cell viability was
determined using the Cellometer method described above. An
average  of  2.0×105  cells/100  μl  was  used  for  each
electroporated sample. Cells were electroporated with either
Silencer negative control #1 siRNA or p21+p16 siRNA as
above.  Following  electroporation,  cells  were  seeded  onto
multiwell chamber slides and incubated in culture medium
with 8% FBS, but without EGF or pituitary extract. At 1, 5,
and 11 days after plating, cells were immunostained for Ki67,
a marker of actively cycling cells [27]. At each time point,
cells were washed quickly 3 times with PBS and then fixed
with 100% methanol for 10 min at −20 °C. All subsequent
steps were performed at room temperature. Cells were washed
3 times in PBS for 10 min each, permeabilized for 10 min with
1% Triton X-100 in PBS, and then washed 3 times in PBS for
10 min each. Non-specific binding was blocked using 4%
BSA in PBS. Cells were incubated for 2 h in pre-diluted mouse
monoclonal Ki67 antibody (Invitrogen-Life Technologies).
Cells were washed 3 times in PBS for 10 min each and then
incubated for 1 h in FITC-conjugated donkey anti-mouse IgG
diluted at 1:200 in 4% BSA in PBS. The cells were washed in
PBS  3  times  for  10  min  each  and  prepared  in  mounting
medium  containing  4’,6  diamidino-2-phenylindole  (DAPI:
Vector  Laboratories,  Burlingame,  CA)  to  stain  all  nuclei.
Digital  fluorescent  images  were  obtained  using  a  Nikon
Eclipse  E800  microscope  with  VFM  epi-fluorescence
attachment (Nikon, Inc., Melville, NY) equipped with a Spot
digital camera and Spot Advanced version 4.5 CE software
(Diagnostic Instruments, Sterling Heights, MI). The number
of Ki67-positive cells and total nuclei were counted in nine
20× magnification fields for each HCEC culture, time point,
and  treatment  condition.  The  average  number  of  cells,
determined  by  counting  DAPI-positive  nuclei,  and  the
average number of Ki67-positive cells were calculated and the
results compared.
Statistical analysis: Statistical analysis for both the western
blot data and the Ki67/DAPI data was performed using the
unpaired Student’s t-test. A p-value of ≤0.05 was considered
to be statistically significant.
RESULTS
Transfer efficiency and viability following electroporation:
Preliminary tests of transfer efficiency were conducted using
different  electroporation  parameters.  Electroporation  of
HCEC  with  Silencer  Cy3-labeled  Negative  Control  #1
siRNA, when conducted under the conditions described in the
“Methods”  section,  yielded  the  best  results.  The
representative fluorescence microscopic image presented in
Figure 1 demonstrates the highly efficient transfer of Cy3-
labeled  siRNA  to  the  cytoplasm  of  cells  within  the
microscopic field. Counts of electroporated samples of HCEC
cultured  from  five  different  donors  compared  with  the
corresponding  non-electroporated  samples  indicate  an
average cell loss of 41.25% at 24 h following electroporation
with a range of 27% to 66% (data not shown).
Down-regulation of p21Cip1 and p16INK4a protein levels
following siRNA treatment: Preliminary western blot studies
were conducted to determine the effect of three different p21
siRNAs (Ambion s415, s416, or s417) on the protein levels of
both p21Cip1 and p16INK4a in cultured HCEC. As shown by
the graphs in Figure 2, at 72 h after electroporation, all three
p21  siRNAs  significantly  reduced  the  level  of  p21Cip1
compared with non-electroporated controls (p≤0.05) and with
controls electroporated with Silencer Cy3-labeled Negative
Control #1 siRNA (p≤0.02). None of the p21 siRNAs induced
a significant change in the expression of p16INK4a (p=0.93
for  all  3  siRNAs  tested).  These  results  demonstrate  the
specificity of the p21 siRNA treatment and provide evidence
that lowering the protein level of p21Cip1 does not result in a
compensatory increase in the level of p16INK4a. Three p16
siRNAs (Ambion s216, s217, s218) were similarly tested and
all three efficiently reduced p16INK4a protein levels, but did
not affect the expression of p21Cip1 (data not shown).
A second series of studies tested the effect of combined
treatment  of  HCEC  with  Ambion  s416  p21  siRNA  plus
Ambion  s217  p16  siRNA  (p21+p16  siRNA).  Cells  were
treated with both siRNAs, because previous work from this
laboratory had indicated that both p21Cip1 and p16INK4a are
expressed at significantly higher levels in HCEC from older
donors,  suggesting  that,  together,  these  two  CKIs  are
responsible for mediating the reduced proliferative response
of HCEC with increasing donor age [25]. HCEC cultured from
three older donors were treated with p21+p16 siRNA and the
effect on the protein expression of both CKIs was determined
by western blot analysis. Results demonstrated that treatment
of HCEC with p21+p16 siRNA consistently decreased the
protein levels of both CKIs. Representative results from a 71-
year-old donor are shown in Figure 3. The graphs in Figure 4
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900show  representative  western  blot  analyses  of  the  relative
protein levels of p21Cip1 and p16INK4a in HCEC from a 68-
year-old donor 2 and 7 days after electroporation with control
or p21+p16 siRNA. Results show similarly decreased levels
of both p21Cip1 and p16INK4a at both time points, indicating
that siRNA treatment remained effective in decreasing the
expression of both CKIs for at least one week.
p21+p16 siRNA treatment promotes cell cycle progression:
The fact that p21+p16 siRNA treatment significantly down-
regulated both CKIs compared with control siRNA provided
a method to test whether p21Cip1 and p16INK4a proteins
negatively regulate G1-phase of the cell cycle and whether
treatment with p21+p16 siRNA would both promote cell cycle
progression and increase cell numbers in HCEC from older
donors. To test these ideas, HCEC from the each of five donors
were treated with either p21+p16 siRNA or Silencer negative
control #1 siRNA and then cultured in the presence of 8%
FBS. On Days 1, 5, and 11 after electroporation, the average
percent of Ki67-positive cells was determined as an indicator
of actively cycling cells and average total cell numbers were
determined by counting total DAPI-stained nuclei. Figure 5
shows  representative  images  of  Ki67-stained  cells  and
Figure 1. Evidence of highly efficient
siRNA  transfer.  HCEC  were
electroporated with 1 μg Silencer Cy3-
labeled Negative Control #1 siRNA and
plated in culture medium as described in
the  “Methods”  section.  This
representative  image  was  taken  24  h
after  electroporation.  Punctate
cytoplasmic staining demonstrates the
high efficiency of siRNA transfer to the
cells. Original magnification: 20×.
Figure 2. Effect of treatment with 3 different p21 siRNAs on p21Cip1 and p16INK4a protein levels. The graph of western blot results in
(A) shows the effect of p21 siRNAs s415, s416, and s417 on the protein level of p21Cip1. The graph in (B) shows the effect of the same 3
p21 siRNAs on the protein level of p16INK4a. In the graphs, each bar shows the average relative expression of p21Cip1 or p16INK4a (+/−
SEM) in HCEC cultured from 3 older donors. Beta-actin was used to normalize all results. Conditions included no electroporation or siRNA
treatment (-E/-siRNA), electroporation with Silencer Cy3-labeled Negative Control #1 siRNA (+E/Cy3control), and electroporation with each
of three siRNAs (+E/p21 s415, s416, or s417).
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old donor treated with control or p21+p16 siRNA. Figure 6
presents  the  overall  results.  The  bar-graph  in  Figure  6A
compares the average percent of Ki67-positive HCEC per 20×
field at each time point. An average of 19% of control cells
had entered the cell cycle on Day 1 compared with 65% of
cells  treated  with  p21+p16  siRNA  (p=0.03).  Under  both
siRNA conditions, the average percent of Ki67-positive cells
decreased over time; however, the percent of Ki67-positive
cells in the p21+p16 siRNA-treated group was higher at each
time point, strongly suggesting that down-regulation of the
expression of p21Cip1 and p16INKa significantly increases
cell cycle entry in HCEC from older donors. The decreasing
number of Ki67-positive cells over the time-frame of the study
suggests  that  there  is  an  increase  in  the  number  of  cells
completing the cell cycle over that period of time. The bar-
graph in Figure 6B compares the average number of cells
present  per  20×  field  for  each  time  point  and  treatment
condition based on counts of DAPI-stained nuclei. Ki67- and
DAPI-stained cells were counted in the same microscopic
Figure 3. Representative example of the effect of treatment with p21+p16 siRNA on the protein levels of p21Cip1 and p16INK4a in HCEC
cultured from a 71-year-old donor. A: Densitometric analysis of the effect of p21+p16 siRNA treatment on p21Cip1 protein expression in
non-electroporated HCEC (-E/-siRNA), in HCEC electroporated with Silencer negative control #1 siRNA (+E/control siRNA), and in HCEC
electroporated with p21+p16 siRNA (+E/p21+p16 siRNA). B: Western blots showing relative expression of p21Cip1 compared with beta-
actin under each experimental condition. C: Densitometric analysis of the effect of p21+p16 siRNA treatment on p16INK4a protein expression
under the same conditions as in A. D: Western blots showing relative expression of p16INK4a compared with beta-actin under each
experimental condition. Results in A and C are expressed relative to beta-actin.
Figure 4. Effect of p21+p16 siRNA on p21Cip1 and p16INK4a protein expression 2 and 7 days following treatment. HCEC from a 68-year-
old donor were electroporated with either control siRNA (+E/control siRNA) or p21+p16 siRNA (+E/p21+p16 siRNA). Western blots were
used to analyze p21Cip1 (A) and p16INK4a (B) protein levels at the 2 time-points. Results are expressed relative to beta-actin. Note that both
p21Cip1 and p16INK4a were decreased to similar levels at both time points.
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902Figure  5.  Representative  fluorescence
microscopic images of actively cycling
HCEC from a 73-year-old donor. HCEC
were  electroporated  with  control  or
p21+p16 siRNA and then seeded onto
multi-well chamber slides. On Days 1,
5,  and  11  after  electroporation,  cells
were immunostained for Ki67 (green) to
view  actively  cycling  cells  and  with
DAPI  (blue)  to  visualize  all  nuclei.
Arrowheads  indicate  Ki67-positive
dividing  cells.  Original  magnification
was 20×.
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903fields. On Day 1, the average number of cells was similar,
regardless  of  the  siRNA  treatment  condition,  indicating  a
similar plating efficiency under the two conditions. In cultures
treated  with  control  siRNA,  the  relative  number  of  cells
increased only slightly on Days 5 and 11, indicating that only
a small percentage of cells had divided, thereby completing
the cell cycle. Statistical analysis did not indicate a significant
difference  in  total  cell  numbers  between  the  control  and
p21+p16  siRNA-treated  groups  for  any  of  the  three  time
points, apparently due to the relatively high scatter in the data.
However,  average  cell  numbers  in  the  p21+p16  siRNA-
treated  group  increased  2.6×  over  the  time  of  the  study
compared with an increase of only 1.1× for cells treated with
control  siRNA.  Together,  these  results  provide  strong
evidence that p21Cip1 and p16INK4a play an important role
in negatively regulating G1-phase of the cell cycle in HCEC
from older donors and that decreasing the protein expression
of these CKIs by siRNA treatment not only promoted cell
cycle entry, but also led to increased cell division.
DISCUSSION
Electroporation  has  been  used  by  several  investigators  to
transfer DNA plasmids to human corneal endothelial cells in
tissue culture [28-30] and in organ culture [31], and in vivo to
Wistar  rats  [32].  Electroporation  was  used  in  the  current
studies to promote efficient transfer of both p21 and p16
siRNA to primary HCEC. The specific method employed was
the  same  as  that  reported  by  Engler  et  al.  [28],  who
successfully transferred cDNA plasmids to primary cultures
of HCEC. In preparation for the current studies, preliminary
experiments were conducted to test corneal endothelial cell
viability and efficiency using several Amaxa-based programs,
including M03, T05, T23, T27, and U11. As was found by
Engler et al. [28], the T23 program yielded the highest transfer
efficiency.  Although  this  method  negatively  affected  cell
viability, most cells survived the treatment, and were healthy
enough to remain attached to the culture dish, to respond to
siRNA  treatment  by  down-regulating  the  expression  of
p21Cip1  and  p16INK4a,  and  to  respond  to  mitogenic
stimulation  by  entering  and  completing  the  cell  cycle  to
produce daughter cells.
The need to develop methods to increase HCEC density
as an in vivo treatment, in ex vivo corneas to be used for
keratoplasty, and in culture for corneal tissue bioengineering
underlies  the  importance  of  identifying  the  molecular
mechanisms  that  regulate  the  HCEC  cell  cycle.  Although
HCEC do not normally divide in vivo, the fact that they retain
proliferative capacity suggests that it should be possible to
find ways to induce transient proliferation in these cells based
on the mechanisms that promote and/or inhibit their division.
Importantly, studies have found that the relative proliferative
capacity of HCEC decreases with donor age [2,6,33]. Western
blot studies have suggested that this age-related difference in
proliferative  capacity  results,  at  least  in  part,  from  the
increased expression and activity of p21Cip1 and p16INK4a
[25]. The current studies targeted HCEC from older donors to
determine whether p21Cip1 and p16INK4a play important
roles in the negative regulation of the cell cycle in these cells
and to determine whether cell division could be enhanced in
cells cultured from this age-group by down-regulating the
expression of these inhibitors.
Results of these studies provide strong evidence that both
p21Cip1 and p16INK4a are involved in negative regulation
of the cell cycle in HCEC and provide an effective barrier to
cell  division.  Results  further  indicate  that  siRNA-induced
reduction in the expression of these proteins results in an
increase in the number of cells entering the cell cycle, as well
as  in  the  number  of  cells  completing  the  cycle,  thereby
increasing total cell numbers. Because HCEC were treated
with a combination of siRNAs that specifically reduce the
protein level of both p21Cip1 and p16INK4a, it is not possible
to assess the relative contribution of each CKI to the inhibitory
Figure 6. Effect of siRNA treatment on cell cycle entry and cell division. HCEC were treated with control or p21+p16 siRNA. On Days 1, 5,
and 11, cells in the same 20× microscopic field were counted to determine the average percent of Ki67-positive cells, as an indication of the
effect of treatment on cell cycle entry (A) and the average total number of DAPI-stained nuclei, as an indication of cell division (B). Data
represents the average results from five different donors. Brackets on each bar represent SEM. P-values are indicated for each condition and
time point.
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904process. However, as indicated above, much is known about
the activity of these inhibitors in other cell types and it is
expected that they would have similar activities in HCEC,
although  the  specific  role  of  each  CKI  should  still  be
investigated in these cells. These results also suggest that
reduction of the levels of p21Cip1 and p16INK4a could be
useful in the development of treatments to induce transient
cell division to increase corneal endothelial cell density.
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